Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure  by Matsuzaki, Masunori et al.
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Background:  Chronic  heart  failure  (CHF)  is  an  increasingly  common  cardiovascular  disease  despite  recent
advances  in  its  diagnosis  and management.
Methods  and  results:  A multicenter,  open-label  study  was  designed  to  assess  the  efﬁcacy  and  safety  of
60-week  treatment  with  candesartan  in  Japanese  patients  with  mild  to moderate  CHF.  Primary  efﬁcacy
endpoints  were  changes  from  baseline  in  plasma  brain  natriuretic  peptide  (BNP),  left  ventricular  ejection
fraction  (LVEF),  end-diastolic  dimension,  and  New  York  Heart  Association  (NYHA)  functional  class.  Two
hundred and  eighty-nine  eligible  patients  were  divided  into  2 groups  based  on  the  daily  dose  at  the
end  of treatment:  high-dose  (HD, 8 mg,  N  =  170)  and  low-dose  (LD,  2 or 4 mg, N =  119).  Neither  plasma
BNP  levels  nor  LVEF  changed  from  the  baseline  to the  end  of  treatment  in the  LD  group,  whereas  BNPngiotensin II receptor blocker
rain natriuretic peptide
eft ventricular ejection fraction
signiﬁcantly  improved  from  61.6  to 50.1  pg/mL  (p =  0.0005)  and  LVEF  from  57.2  to  60.1%  (p =  0.0005)  in
the  HD  group.  The  changes  in NYHA functional  class  were  comparable  between  groups:  21.2%  improved
and  76.3%  unchanged  in the  LD group and  20.6%  improved  and  79.4%  unchanged  in the  HD group.  No
safety  concerns  were  observed  in either  group.
Conclusions:  HD  candesartan  was  more  effective  in  improving  plasma  BNP  levels  and cardiac  function
patien
3  Japthan  LD  in  Japanese  CHF  
©  201
ntroduction
Chronic heart failure (CHF) is an increasingly common cardio-
ascular disease and is the major cause of morbidity and mortality
hroughout the world [1–3]. Patients with CHF are at high risk
or death and hospitalization for worsening HF. In Japan, approxi-
ately 1–2 million adults have CHF and more than 180,000 patients
ie of heart diseases each year with a death rate of approximately
40 per 100,000 persons [4].
For the treatment of hypertension and HF, angiotensin-
onverting-enzyme (ACE) inhibitors have been widely used
s ﬁrst-line drugs [1,2]. Angiotensin II receptor blockers
ARBs) have emerged as an alternative for inhibiting the
enin–angiotensin–aldosterone system by selectively block-
ng the angiotensin II type 1 receptor. Candesartan is an ARB
DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2012.12.017.
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ttp://dx.doi.org/10.1016/j.jjcc.2012.12.004ts.  Both  LD and  HD  candesartan  were  well  tolerated  in CHF patients.
anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
having a long-acting antihypertensive effect due to its lower
dissociation rate from the angiotensin type 1 receptor [5].
A randomized, double-blind, placebo-controlled Assessment of
Response to Candesartan in HF in Japan (ARCH-J) study evaluat-
ing the efﬁcacy and safety of 6-month treatment with candesartan
8 mg  once daily in patients with congestive HF demonstrated
that the incidence of conﬁrmed progression of congestive HF was
signiﬁcantly lower in the candesartan group, especially in the sub-
group of patients previously treated with ACE inhibitors, than
in the placebo group (7.4% vs. 22.2%) with a risk reduction of
66.7% and a risk difference of −14.8% (p < 0.001) [6].  Based on
these results, an additional indication for candesartan for the treat-
ment of mild to moderate CHF in patients for whom treatment
with ACE inhibitors is inappropriate was  approved in Japan in
2005.
In order to collect and analyze data on the frequency and back-
ground factors of dose escalation/reduction in a clinical setting, we
conducted a study to assess the efﬁcacy and safety of 60-week treat-
ment with candesartan in Japanese patients with mild to moderate
CHF.
vier Ltd. All rights reserved.
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ubjects and methods
tudy design
The study design is shown in Fig. 1. This study was a multi-
enter, open-label study consisting of a 4-week run-in period and a
0-week treatment period. The starting dose of candesartan for the
reatment of CHF was 4 mg  once daily, which could be increased up
o 8 mg  once daily as needed. An alternative starting dose of 2 mg
nce daily was recommended for a period not exceeding 4 weeks
or patients who had systolic blood pressure (SBP) of <120 mmHg,
enal dysfunction, severe HF, or those given diuretics concomi-
antly. All patients received candesartan, starting at a dose of either
 or 4 mg  once daily, which was increased to 8 mg  once daily by
eek 12 as tolerated and needed. Dose escalation/reduction was
ecided upon as needed during the treatment period. Patients vis-
ted the study sites every 2–4 weeks (every 4 weeks in principle)
rom week −4 to week 60. Throughout the study period, concomi-
ant medication for HF was allowed except for ACE inhibitors and
RBs.
tudy patients
Japanese outpatients with mild to moderate CHF who
et  the following inclusion criteria were enrolled: age ≥ 20
ears; previously treated with ACE inhibitors regardless of
uration; considered unsuitable by the investigators for treat-
ent with ACE inhibitors; and New York Heart Association
NYHA) functional class II–III. The main exclusion criteria
ncluded: unstable angina; serious ventricular arrhythmia;
erious valvular stenosis; hypertrophic obstructive cardiomy-
pathy; acute myocardial infarction within 4 weeks before
he start of treatment; cerebrovascular disease, coronary-
rtery bypass graft (CABG) surgery or percutaneous coronary
ntervention (PCI) within 12 weeks before the start of treat-
ent; CABG or PCI implemented or scheduled after the
tart of the study; cardiogenic shock or SBP < 80 mmHg;
erious respiratory disease; renal artery stenosis; hyper-
alemia; pregnant or nursing women or women suspected
f being pregnant; or patients considered ineligible by the
nvestigators.The study was performed at 50 centers in Japan between June
006 and July 2008 in accordance with the Declaration of Helsinki,
he International Conference on Harmonization and the Harmo-
ized Tripartite Guidelines on Good Clinical Practice (GCP), and was
Trea tment (A
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mg/day 
Dose e
Wee 
Dose
Prior treat ment 
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Fig. 1. Study design. ACE, angiotdiology 61 (2013) 267–274
approved by the Institutional Review Board at each study site. All
patients provided written informed consent.
Study protocol
NYHA functional class, vital signs, adverse events (AEs), and the
medication adherence were examined every 4 weeks throughout
the study period. Echocardiography, a resting 12-lead electrocar-
diogram (ECG), and other laboratory tests were performed and
assessed every 12 weeks.
Study endpoints
The primary efﬁcacy endpoints were the changes from baseline
in plasma brain natriuretic peptide (BNP), left ventricular ejection
fraction (LVEF), left ventricular end-diastolic dimension (LVDd),
and NYHA functional class at the end of treatment, using last
observation carried forward data analysis. Other efﬁcacy measures
included the changes from baseline in left ventricular end-systolic
dimension (LVDs), 12-lead ECG ﬁndings, and body weight at the
end of treatment. The following outcome measures were assessed:
adverse drug reactions, cardiovascular events, death from cardio-
vascular events, hospitalization or death due to HF deterioration,
nonfatal myocardial infarction, and addition or dose escalation of
concomitant medications for HF (continuous oral medication over
2 weeks). Reasons for considering ACE inhibitor treatment inappro-
priate, and dose escalation/reduction or continuation of the same
dose were also recorded.
Statistical analysis
To allow for possible withdrawals/discontinuations, we planned
to enroll 300 patients in the clinical study. For the primary efﬁcacy
endpoints, the mean, standard deviation (SD), and the two-sided
95% conﬁdence interval (CI) were calculated by applying a one-
sample t test. The distributions of the data of changes in plasma
BNP were highly skewed by outliers. Therefore, the geometric
means and the two-sided 95% CIs were calculated by converting
the means of log-transformed BNP values and the two-sided 95%
CIs back to the original scale using back transformation for these
indices. For these variables, a one-sample t test was performed by
using log-transformed values. Eligible patients were divided into
2 groups based on the candesartan dose at the end of treatment:
low-dose (LD, 2 or 4 mg)  and high-dose (HD, 8 mg). To compare the
2 groups, analysis of covariance (ANCOVA) was performed using
dministration  of candesar tan) 
scalation  up  to  8 mg once  dail y was made  by 
k 12  as  tole rated  and  needed  by the  patients . 
 escalation  or  reduction  was made as needed  
during  the  treat ment  pe riod . 
lockers, va sodil ators or other ino tropic  agents (dos e 
mmended  dosage  and  administ ration)  
t every 2 to 4 weeks
 4 week s in  principle) 
      60
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ensin-converting enzyme.
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D and HD as independent variables and baseline values as covari-
tes for the primary endpoints (dependent variables) except for the
YHA class for which Fisher’s exact test was carried out. For the
hange from baseline of the log-transformed BNP and the change
rom baseline of LVEF and LVDd, ANCOVA was also performed using
he dose at the end of treatment (LD or HD) as the independent
ariable, and baseline values as covariates. For the safety evalu-
tion, SBP, diastolic blood pressure (DBP), pulse rate, estimated
lomerular ﬁltration rate (eGFR), and hemoglobin were analyzed
s well. The efﬁcacy endpoints were evaluated in the full analysis
et (FAS) and the AEs were assessed in the safety analysis set (SAS).
or all statistical analysis, the signiﬁcance level was set at 0.05
two-sided).
esults
tudy patientsOut of 308 patients enrolled in this study, 19 were excluded due
o a major violation of GCP and the remaining 289 were included in
he FAS and SAS population. Of these 289 patients, 252 completed
he study medication and 37 discontinued the medication due to
able 1
emographic and baseline clinical characteristics.
Item/category 
No. of patients
Age (years)
33–64 
65–74  
75–89  
Gender
Male
Female 
Height (cm) 
Body  weight (kg)
BMI  (kg/m2) 
NYHA  functional class
Class I 
Class IIS
Class  IIM
Class  III 
Class  IV 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Cardiothoracic ratio (%) 
Brain  natriuretic peptide (pg/mL) 
Left  ventricular end-diastolic dimension (mm)  
Left  ventricular end-systolic dimension (mm)
Left  ventricular ejection fraction (%) 
Major  cause of HF
Dilated cardiomyopathy 
Ischemic heart disease 
Hypertensive heart disease 
Valvular disease 
Other 
Duration of HF (years) 
ACE  inhibitors/ARBs discontinued within 12 weeks before the start of the treatment pe
Concomitant medications for HF at the beginning of treatmenta
Overall 
Diuretic 
Beta  blocker 
Digoxin/digitoxin 
Vasodilator 
Other  
MI, body mass index; NYHA, New York Heart Association; HF, heart failure; LD, low-
ngiotensin-converting enzyme; ARB, angiotensin receptor blocker. Values are presented
a One patient may  have 2 or more concomitant medications.diology 61 (2013) 267–274 269
AEs in 27 patients, major protocol deviation in 2 patients, sponta-
neous withdrawal in 2 patients, and other reasons in 6 patients.
Most patients (98.6%) had medication adherence rates of at least
90%.
The demographic and baseline clinical characteristics are sum-
marized in Table 1. Plasma BNP, LVEF, LVDd, and LVDs values at the
baseline did not differ between the groups.
The most common reason for considering ACE inhibitor treat-
ment inappropriate was “cough” [95.2% (275/289 patients)],
followed by “decreased blood pressure” [0.7% (2/289 patients)].
The dose adjustment scheme during the treatment period is
summarized in Table 2. The starting dose was 4 mg  once daily in
70.9% of patients (205/289) and 2 mg  once daily in 29.1% (84/289).
The daily dose at the end of treatment was  8 mg  in 58.8% of patients
(170/289), 4 mg  in 40.5% (117/289), and 2 mg in 0.7% (2/289).
Regarding dose adjustment, the most common reason for con-
tinuing the 4-mg dose was  “dose escalation not needed because
response is sufﬁcient” (63.7%). Among the reasons for increasing
the dose to 8 mg, “higher efﬁcacy of the drug anticipated” (85.9%)
was more common than “insufﬁcient response” (12.4%). The most
common reason for continuing the dose of 8 mg  was  “being well
tolerated” (99.9%).
Total LD HD p-Value
289 119 170
102 (35.3) 47 (39.5) 55 (32.4)
114 (39.4) 37 (31.1) 77 (45.3)
73 (25.3) 35 (29.4) 38 (22.4)
67.5 ± 9.8 67.4 ± 10.7 67.5 ± 9.2 0.9389
187 (64.7) 79 (66.4) 108 (63.5)
0.6169102 (35.3) 40 (33.6) 62 (36.5)
159.6 ± 9.2 159.6 ± 8.8 159.7 ± 9.6 0.9776
63.1 ± 12.7 62.2 ± 12.0 63.7 ± 13.2 0.3496
24.6 ± 3.8 24.3 ± 3.5 24.8 ± 4.0 0.2301
0 (0.0) 0 (0.0) 0 (0.0)
0.4357
196 (67.8) 79 (66.4) 117 (68.8)
66 (22.8) 31 (26.1) 35 (20.6)
27 (9.3) 9 (7.6) 18 (10.6)
0 (0.0) 0 (0.0) 0 (0.0)
129.1 ± 16.7 123.9 ± 14.8 132.7 ± 17.0 <0.0001
73.4 ± 11.5 70.4 ± 9.8 75.6 ± 12.1 0.0001
53.0 ± 6.2 52.6 ± 6.0 53.3 ± 6.3 0.3804
125.5 ± 172.4 122.4 ± 183.7 127.7 ± 164.5 0.7957
51.7 ± 8.2 52.4 ± 9.1 51.2 ± 7.5 0.2295
36.2 ± 10.1 37.1 ± 10.9 35.6 ± 9.6 0.236
56.8 ± 15.6 56.1 ± 14.7 57.2 ± 16.1 0.5397
52 (18.0) 23 (19.3) 29 (17.1)
0.0063
91 (31.5) 42 (35.3) 49 (28.8)
60 (20.8) 12 (10.1) 48 (28.2)
57 (19.7) 28 (23.5) 29 (17.1)
29 (10.0) 14 (11.8) 15 (8.8)
4.9 ± 4.1 5.9 ± 4.5 4.2 ± 3.6 0.0005
riod 154 (53.3) 56 (47.1) 98 (57.6) 0.0758
208 (72.0) 91 (76.5) 117 (68.8) 0.1543
149 (51.6) 77 (64.7) 72 (42.4) 0.0002
102 (35.3) 43 (36.1) 59 (34.7) 0.8025
88 (30.4) 37 (31.1) 51 (30.0) 0.8426
19 (6.6) 8 (6.7) 11 (6.5) 0.9322
13 (4.5) 8 (6.7) 5 (2.9) 0.1269
dose group (2 or 4 mg once daily); HD, high-dose group (8 mg once daily); ACE,
 as n (%) or mean ± SD.
270 M. Matsuzaki et al. / Journal of Car
Table 2
Dose adjustment scheme during the treatment period.
Item/category Total
n (%)
No. of patients 289
Dose adjustment
2 mg  once daily 2 (0.7)
2  → 4 mg  once daily 42 (14.5)
2  → 4 → 8 mg  once daily 37 (12.8)
2  → 4 → 8 → 4 mg  once daily 3 (1.0)
4  mg  once daily 68 (23.5)
4  → 8 mg  once daily 133 (46.0)
4 → 8 → 4 mg  once daily 4 (1.4)
Starting dose
2 mg  once daily 84 (29.1)
4  mg  once daily 205 (70.9)
Dose at the end of treatment
2  mg  once daily 2 (0.7)
4  mg  once daily 117 (40.5)
V
E
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w8  mg  once daily 170 (58.8)
alues represent number (%) of patients.
fﬁcacy
The geometric mean of BNP signiﬁcantly declined from
0.9 pg/mL to 55.3 pg/mL at week 24 and remained at a low level
hrough to week 60 (49.5 pg/mL). At the end of treatment, the
eometric mean of BNP was 53.2 pg/mL and the ratio to the base-
ine value was 0.87 [two-sided 95% CI (0.798 to 0.955)], indicating
 signiﬁcant BNP reduction from the baseline (p = 0.0030). With
NCOVA, using the ﬁnal dose as factor and the baseline value
s covariate, the regression coefﬁcients of BNP to the effect of
he baseline values were signiﬁcant negative values. In terms of
NP changes, the higher the baseline level, the greater was the
NP reduction observed: each ratio to baseline value was 0.86
n 20 ≤ BNP < 100 pg/mL (n = 127), 0.77 in 100 ≤ BNP < 200 pg/mL
n = 49), and 0.71 in BNP ≥ 200 pg/mL (n = 56). No positive relation-
hip was found between the reduction of BNP and patient age or
ender.The time course of BNP changes in the LD and HD groups is
hown in Fig. 2. The geometric mean BNP levels in the HD group
igniﬁcantly declined from 61.6 pg/mL at baseline to 54.7 pg/mL at
eek 24 and remained at a low level up to week 60 (46.2 pg/mL),
Fig. 2. Time course of plasma brain natriuretic peptide (BNP)diology 61 (2013) 267–274
whereas no signiﬁcant changes occurred in the LD group. At the
end of treatment, the geometric mean BNP value was  50.1 pg/mL
and the ratio to the baseline value was  0.81 in the HD group [95% CI
(0.726 to 0.912)] (p = 0.0005). Plasma BNP at the end of treatment
also tended to be lower in the HD group than in the LD group, but
did not reach statistical signiﬁcance (p = 0.0527).
Mean LVEF signiﬁcantly increased from 56.8% at the baseline
to 58.2% at week 12 and remained at a similar level until week
60. At the end of treatment, mean LVEF was 58.4% and the mean
value of individual percent change from the baseline was 6.8%
[95% CI (2.97 to 10.56)] (p = 0.0005). With ANCOVA, using the ﬁnal
dose as factor and the baseline value as covariate, the regression
coefﬁcients of LVEF to the effect of the baseline values were sig-
niﬁcant negative values. In terms of LVEF changes, the lower the
baseline level, the higher was  the improved rate obtained: the per-
cent change from the baseline was  37.5% in LVEF < 40.0% (n = 45),
5.3% in 40 ≤ LVEF < 55% (n = 70), and −0.7% in LVEF ≥ 55% (n = 172).
No positive relationship was found between LVEF increase and
patient age or gender.
The time course of LVEF changes in the LD and HD groups is
shown in Fig. 3. In the LD group, no signiﬁcant LVEF changes were
found throughout the treatment period and the mean value of indi-
vidual percent change from the baseline was  2.0% [95% CI (−2.63
to 6.59)] at the end of treatment. In the HD group, the mean LVEF
signiﬁcantly increased from 57.2% at the baseline to 59.3% at week
12, reached the maximal value (60.8%) at week 48, and remained
at a high level through to week 60 (60.7%). At the end of treatment,
the mean LVEF was 60.1% and the mean value of individual per-
cent change from the baseline was 10.1% [95% CI (4.51 to 15.61)]
(p = 0.0005). A signiﬁcant difference in the percent changes from the
baseline in LVEF [9.0%, 95% CI (2.26 to 15.83)] was  found between
the LD and HD groups at the end of treatment (p = 0.0092), indicat-
ing a dose–response relationship.
The time course of LVDd changes in the LD and HD groups is
shown in Fig. 3. Changes from the baseline in LVDd were minimal
throughout the treatment period. At the end of treatment, the mean
LVDd was 52.0 mm (mean percent change from baseline, −0.2%) in
the LD group and 50.1 mm (mean percent change from baseline,
−1.7%) in the HD group. There were no signiﬁcant differences in
the percent changes from the baseline LVDd values [−2.0%, 95% CI
(−4.65 to 0.64)] between the LD and HD groups.
 levels in the low-dose (LD) and high-dose (HD) groups.
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dig. 3. Time course of echocardiography parameters in LD and HD groups. LVEF, l
ose; HD, high dose.
Of the 119 patients in the LD group, 79 were in NYHA functional
lass IIS, 31 in IIM, and 9 in III at baseline (Fig. 4). NYHA func-
ional class progressively improved after the start of treatment and
howed the maximal improvement in 23.8% of patients (24/101)
t week 56. At the end of treatment, 21.2% of patients (25/118)
howed an improvement, but 76.3% (90/118) were without change.
eterioration occurred in 2.5% of patients (3/118).
Of the 170 patients in the HD group, 117 were in class IIS, 35 in
IM, and 18 in III at baseline (Fig. 4). The improved rate increased
oon after the start of treatment and reached the maximal value,
mprovement in 20.8% of patients (32/154) at week 60. At the end
f treatment, 20.6% of patients (35/170) exhibited an improvement,
ut 79.4% (135/170) were without change. No patients experienced
eterioration of NYHA functional class. With the Wilcoxon signedtricular ejection fraction; LVDd, left ventricular end-diastolic dimension; LD,  low
rank test, signiﬁcant differences were found between the changes
in NYHA functional class in patients before and after the treatment
in both the HD and the LD groups (p < 0.001).
HF-associated events occurred in 18.3% of study patients
(53/289), 19.3% (23/119) in the LD group, and 17.6% (30/170) in
the HD group (Table 3). The incidences of HF-associated events did
not differ between the LD and HD groups.
SafetyA total of 1059 treatment-emergent AEs were reported in 92.4%
of patients (267/289). There were 65 serious AEs reported in 17.0%
of patients (49/289), which included 3 deaths (3/289, 1.0% of
patients). Among the serious AEs, 4 drug-related AEs occurred in
272 M. Matsuzaki et al. / Journal of Cardiology 61 (2013) 267–274
Fig. 4. Changes in New York Heart Association functional class in the low-dose (LD)
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Table 4
Vital signs, eGFR, and hemoglobin at baseline and at the end of treatment in LD and
HD groups.
Week 0 End of treatment p-Value*
Mean ± SD Mean ± SD
Systolic BP (mmHg)
LD 123.9 ± 14.8 118.7 ± 15.9
0.0003HD 132.7 ± 17.0 129.6 ± 17.6
Diastolic BP (mmHg)
LD 70.4 ± 9.8 68.4 ± 11.2
0.0556HD  75.6 ± 12.1 73.1 ± 12.5
Pulse ratea (beats/min)
LD 72.8 ± 10.3 74.0 ± 10.1
0.0686HD 72.8 ± 11.9 71.8 ± 12.1
eGFR (mL/min/1.73 m2)
LD 65.3 ± 17.5 64.7 ± 17.9
0.2008HD  63.5 ± 18.3 62.1 ± 18.1
Hemoglobin (g/dL)
LD 13.6 ± 1.6 13.2 ± 1.7
0.9143HD  13.6 ± 1.8 13.2 ± 1.9
BP, blood pressure; eGFR, estimated glomerular ﬁltration rate; LD, low-dose group
(2  or 4 mg once daily); HD, high-dose group (8 mg  once daily).
a
the HD groups in this study and these values were higher than
T
H
H
Nnd  high-dose (HD) groups.
.4% (4/289), including acute pyelonephritis, cerebral hemorrhage,
ertigo, and angina pectoris (1 event each). Drug-related AEs lead-
ng to discontinuation occurred in 3.8% of patients (11/289).
The incidence of drug-related AEs was slightly higher in the LD
23.5% (28/119 patients)] than in the HD [17.1% (29/170 patients)]
roup, but no signiﬁcant differences in severity or class of drug-
elated events were found between groups.
No clinically signiﬁcant abnormalities were observed in the vital
igns and clinical laboratory test results. Mean values (SD) of SBP,
BP, pulse rate, eGFR, and hemoglobin at baseline and at the end of
reatment are shown in Table 4. The adjusted mean SBP change in
he LD group had a statistically signiﬁcant larger value than that in
he HD group [−8.2 mmHg  in the LD group and −1.3 mmHg  in the
able 3
F-associated events in total patients of LD and HD groups.
HF-associated events Total (
Any of the overall events 53 (18.
Either hospitalization for HF deterioration, or addition or dose
escalation of concomitant medications for HFa
44 (15.
Cardiovascular events 21 (7.3
Death from cardiovascular events 1 (0.3
Hospitalization for HF deterioration 7 (2.4
Hospitalization for or death from HF deterioration 7 (2.4
Nonfatal myocardial infarction 0 (0.0
Addition or dose escalation of concomitant medications for HFa 41 (14.
F, heart failure; LD, low-dose group (2 or 4 mg  once daily); HD, high-dose group (8 mg o
o  signiﬁcant differences in the incidences of HF-associated events were found between 
a Continuous oral medication over 2 weeks.Pulse rates of patients with atrial ﬁbrillation were also included in these results.
* p-Values were calculated by ANCOVA using baseline value as covariates and the
ﬁnal dose as an independent variable.
HD group (p = 0.0003)]. There were no other signiﬁcant differences
in the other parameters.
Overall, a 60-week treatment with recommended candesartan
doses was well tolerated in patients with mild to moderate CHF.
Discussion
This study was  designed to closely represent the clinical use
of recommended doses of candesartan. In most patients, the dose
was increased from 4 mg  to 8 mg  at a time point between week
4 and week 12, in anticipation of a higher efﬁcacy of candesar-
tan. Long-term treatment with candesartan resulted in signiﬁcant
changes from the baseline in plasma BNP levels and LVEF as well
as an improvement in NYHA functional class. The improvements in
BNP levels and LVEF were signiﬁcantly greater in the HD than in the
LD group, while NYHA functional class improved in approximately
20% of patients in both groups.
In the ARCH-J study in Japanese patients with congestive HF, 6-
month treatment with candesartan 8 mg  once daily signiﬁcantly
reduced the progression of congestive HF compared with the
placebo (7.4% vs. 22.2%) and the development of cardiovascular
events (10.8% vs. 22.9%) [6].
Mean baseline LVEF values were 56.1% in the LD and 57.2% inthat (35.3%) in the candesartan group in the ARCH-J study. The
proportion of patients with more preserved LVEF was  higher in this
study than in the ARCH-J study suggesting that these patients were
N = 289) LD (N = 119) HD (N = 170) p-Value
3) 23 (19.3) 30 (17.6) 0.528
2) 19 (16.0) 25 (14.7) 0.6165
) 8 (6.7) 13 (7.6) 0.9132
) 1 (0.8) 0 (0.0) 0.2193
) 3 (2.5) 4 (2.4) 0.855
) 3 (2.5) 4 (2.4) 0.855
) 0 (0.0) 0 (0.0) –
2) 17 (14.3) 24 (14.1) 0.7792
nce daily). Values represent number (%) of patients who had HF-associated events.
the LD and HD groups with the log-rank test.
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onsidered to be at relatively low risk for cardiovascular mortality
3,7,8].  In the present study, in terms of LVEF changes, the lower
he baseline level, the higher the improved rate obtained. The
VEF change from 57.2% at the baseline to 60.7% at week 60 in the
D group was less than that (from 35.1% to 40.9%) with 6-month
andesartan treatment in the ARCH-J study. This lower degree of
mprovement in LVEF might be due to the high baseline LVEF levels
n the present study and the differences in the underlying diseases
f HF, complications such as hypertension and diabetes, treatment
uration, and concomitant medications between these 2 studies.
he underlying diseases of HF in the candesartan group in the
RCH-J study were dilated cardiomyopathy (55.4%), myocardial
nfarction (23.0%), hypertension (7.4%), and valvular disease (4.1%).
As is well known, plasma BNP was reported to be an impor-
ant predictor of mortality and ﬁrst morbid event in CHF [9].  Mean
aseline BNP levels, 122.4 pg/mL (median, 64.0 pg/mL) in the LD
nd 127.7 pg/mL (median, 74.1 pg/mL) in the HD groups, in this
tudy were lower than the 181 pg/mL (median, 97 pg/mL) reported
n patients enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
10]. In the present study, a higher baseline BNP level was  associ-
ted with a greater reduction due to treatment with candesartan.
imilar effects were also reported in the Val-HeFT [10]. These ﬁnd-
ngs suggest that a signiﬁcant BNP-reducing effect was not obtained
peciﬁcally with the LD treatment possibly because of the low base-
ine BNP levels in the present study population.
The overall incidences of HF-associated events were 19.3% in
he LD and 17.6% in the HD groups; the addition/dose increase
f HF medication (14.3% in the LD and 14.1% in the HD group),
ardiovascular events (6.7% in the LD and 7.6% in the HD group),
nd hospitalization or death due to worsening HF (2.5% in the LD
nd 2.4% in the HD group). These results were comparable with a
peciﬁed drug-use results survey of candesartan in 1087 Japanese
HF patients, in which cardiovascular events and hospitalization or
eath due to HF occurred in 2.9% and 6.0% of patients, respectively,
uring a 1-year observation period (from the data attached to the
eexamination applications). The incidence of the addition/increase
f HF medication in this study was higher than that in the ARCH-J
tudy (2.0%) and those of cardiovascular events and hospitalization
or HF were lower (10.8% and 5.4%, respectively). These differences
ight be attributable to the high baseline LVEF levels in the present
tudy patients and the differences in the underlying diseases of HF,
omplications, and treatment conditions between these 2 studies.
Previous large-scale clinical trials of candesartan, valsartan, and
osartan for CHF demonstrated that signiﬁcant reductions in cardio-
ascular mortality and morbidity were produced by high-dose ARBs
itrated as tolerated to the target doses [11–14]. In the treatment
ith candesartan for patients with symptomatic HF, high-dose
reatment titrated as tolerated to a target dose of 32 mg  once daily
mean daily dose of 24 mg)  reduced cardiovascular death and hos-
italization for HF [11,12].  These studies indicate that the highest
ossible dose of candesartan tolerated by patients is preferable. The
resent results are also considered to be in agreement with these
tudies.
tudy limitations
This study has a couple of limitations. Firstly, this was not a ran-
omized double-blinded study, and therefore the decision about
ose titration of candesartan was delegated to each physician. Thus,
he dose may  have been affected by the patient background and
tatus: lower SBP in the LD group might have caused hesitation
o titrate the dose further. Secondly, the population enrolled in
his study showed CHF of relatively mild severity. Consequently,
he degree of improvement was relatively small, especially in the
D group. However, despite these limitations, this study reﬂects
he clinical practice in the real-world of CHF treatment in Japandiology 61 (2013) 267–274 273
showing the effects of candesartan within the range of approved
doses.
Conclusions
A 60-week treatment with the recommended regimen signif-
icantly improved plasma BNP levels, LVEF, and NYHA functional
class and candesartan was  well tolerated in Japanese patients with
mild to moderate CHF. Improvements in plasma BNP levels and
LVEF were signiﬁcantly greater with the higher dose of candesartan
treatment.
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